https://www.live-feeds.com/feed/daraxonrasib-for-previously-treated-ras-mutant-non-small-cell-lung-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/daraxonrasib-for-previously-treated-ras-mutant-non-small-cell-lung-cancerhttps://www.live-feeds.com/feed/daraxonrasib-for-previously-treated-ras-mutant-non-small-cell-lung-cancer#u65381Fri, 11 Sep 2026 19:20:36 +0000The FDA approved Rasonque in August 2026, a drug also known as daraxonrasib. While the medication is already authorized for metastatic pancreatic cancer, early trials indicate it may effectively treat lung cancer in patients who do not respond to standard therapies. Clinical results involving patients at the Memorial Sloan Kettering Cancer Center have been released to evaluate the drug's efficacy for RAS-mutant non-small-cell lung cancer. Access remains a concern due to high costs associated with advanced oncology treatments.Why it mattersRAS-mutant non-small-cell lung cancer often resist https://www.live-feeds.com/feed/daraxonrasib-for-previously-treated-ras-mutant-non-small-cell-lung-cancerhttps://www.live-feeds.com/feed/daraxonrasib-for-previously-treated-ras-mutant-non-small-cell-lung-cancer#u59366Mon, 07 Sep 2026 02:52:36 +0000Researchers are evaluating daraxonrasib for patients with previously treated RAS-mutant non-small-cell lung cancer. The drug, which the FDA approved for pancreatic cancer to improve survival, is now being studied for its potential efficacy in lung cancer. A related medication from RevMed, Rasonque, has also received approval and may be viable for non-small cell lung cancer. Some of these advanced cancer treatments carry high costs, with one pill priced at $480,000 per year.Why it mattersRAS mutations are common drivers in various cancers, making targeted inhibitors critical for patients who fa